amlodipine has been researched along with Bright Disease in 9 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 9.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| " The present study compared the chronic effects of efonidipine and amlodipine on proteinuria in patients with chronic glomerulonephritis." | 9.12 | Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. ( Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Numabe, A; Ohta, S; Ono, H; Takahashi, T; Yoshii, M, 2007) |
| "Hydralazine is a medication that has been used to manage hypertension and heart failure." | 7.80 | Hydralazine associated pauci-immune glomerulonephritis. ( Baiswar, S; Suneja, M; Vogelgesang, SA, 2014) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 5.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| " The present study compared the chronic effects of efonidipine and amlodipine on proteinuria in patients with chronic glomerulonephritis." | 5.12 | Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. ( Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Numabe, A; Ohta, S; Ono, H; Takahashi, T; Yoshii, M, 2007) |
| " Our aim was to prospectively compare the effects of amlodipine and ACEI (enalapril) on renal function in hypertensive patients with renal impairment due to chronic glomerulonephritis and essential hypertension." | 5.09 | Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. ( Hayashi, K; Kumagai, H; Kumamaru, H; Saruta, T, 2000) |
| "Hydralazine is a medication that has been used to manage hypertension and heart failure." | 3.80 | Hydralazine associated pauci-immune glomerulonephritis. ( Baiswar, S; Suneja, M; Vogelgesang, SA, 2014) |
| "The results of this study suggested that the L/N-type CCB, cilnidipine, had additive antihypertensive and proteinuria-lowering effects when administered in combination with an ARB, even in type-1 diabetic rats, and that the L-type CCB, amlodipine, did not." | 3.79 | Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. ( Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T, 2013) |
| "Our data show that the effects of losartan and amlodipine on the absolute mean reduction of blood pressure and proteinuria in non-diabetic nephropathy patients are similar between the different ACE or AGT genotypes." | 3.73 | [Pharmacogenetics of angiotensin system in non diabetic nephropathy]. ( Alvarez, V; Arias, M; Campistol, JM; Coto, E; Fernández Andrade, C; Galcerán, JM; Luño, J; Marín, R; Poveda, R; Praga, M; Rivera, F; Vallés, M, 2005) |
| "Poststreptococcal glomerulonephritis is the best known example." | 1.48 | Acute infection-related glomerulonephritis with disseminated gonococcal infection in a 13-year-old girl. ( Chandra, M; D'Agati, V; Krilov, LR; Noor, A, 2018) |
| "Patients with immunoglobulin A nephropathy administered ACE inhibitors showed significantly lower renal TGF-beta1 gene expression than patients not administered these medications (mean ratios of TGF-beta1/beta-actin, 4." | 1.31 | ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. ( Kim, D; Kim, HS; Kim, SJ; Ma, KA; Shin, GT, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noor, A | 1 |
| Krilov, LR | 1 |
| D'Agati, V | 1 |
| Chandra, M | 1 |
| Suneja, M | 1 |
| Baiswar, S | 1 |
| Vogelgesang, SA | 1 |
| Aritomi, S | 2 |
| Koganei, H | 1 |
| Wagatsuma, H | 1 |
| Mitsui, A | 1 |
| Ogawa, T | 2 |
| Nitta, K | 2 |
| Konda, T | 2 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, N | 1 |
| Matsumoto, S | 1 |
| Maruyama, T | 1 |
| Fujita, T | 1 |
| Matsumoto, K | 1 |
| Soma, M | 1 |
| Niinuma, K | 1 |
| Coto, E | 1 |
| Marín, R | 1 |
| Alvarez, V | 1 |
| Praga, M | 1 |
| Fernández Andrade, C | 1 |
| Arias, M | 1 |
| Poveda, R | 1 |
| Vallés, M | 1 |
| Galcerán, JM | 1 |
| Luño, J | 1 |
| Rivera, F | 1 |
| Campistol, JM | 1 |
| Ishimitsu, T | 1 |
| Kameda, T | 1 |
| Akashiba, A | 1 |
| Takahashi, T | 1 |
| Ohta, S | 1 |
| Yoshii, M | 1 |
| Minami, J | 1 |
| Ono, H | 1 |
| Numabe, A | 1 |
| Matsuoka, H | 1 |
| Kumagai, H | 1 |
| Hayashi, K | 1 |
| Kumamaru, H | 1 |
| Saruta, T | 1 |
| Shin, GT | 1 |
| Kim, SJ | 1 |
| Ma, KA | 1 |
| Kim, HS | 1 |
| Kim, D | 1 |
3 trials available for amlodipine and Bright Disease
| Article | Year |
|---|---|
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2011 |
Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
Topics: Adult; Aged; Aldosterone; Amlodipine; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L- | 2007 |
Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Captopril; Chr | 2000 |
6 other studies available for amlodipine and Bright Disease
| Article | Year |
|---|---|
Acute infection-related glomerulonephritis with disseminated gonococcal infection in a 13-year-old girl.
Topics: Acute Disease; Adolescent; Amlodipine; Anti-Bacterial Agents; Antihypertensive Agents; Biopsy; Ceftr | 2018 |
Hydralazine associated pauci-immune glomerulonephritis.
Topics: Aged; Aged, 80 and over; Amlodipine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Ant | 2014 |
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; | 2010 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; B | 2013 |
[Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel | 2005 |
ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Block | 2000 |